Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Catalent, Inc

https://www.catalent.com/

Latest From Catalent, Inc

Novo Dips Into Money Pile Again To Boost Obesity Drug Manufacturing

Bookmark
  • News
By Kevin Grogan

The Danish drugmaker is investing over $4.1bn on a second facility in North Carolina for its GLP-1 therapies but has abandoned plans to build a new plant in Dublin, Ireland.

Manufacturing Metabolic Disorders

Competitive Dealmaking Market Shifts To Smaller M&A, Partnering

Bookmark
  • Analysis
By Mandy Jackson

Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.

BIO Deals

BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More

Bookmark
  • News
By Pink Sheet Team

Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act," Novo Nordisk's business development head talking about spending its semaglutide bounty, Roivant's  long view on BD prospects for Immunovant's FcRn inhibitor, and more regulatory concerns around artificial intelligence. 

BIO Deals

BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More

Bookmark
  • News
By Scrip Team

Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act," Novo Nordisk's business development head talking about spending its semaglutide bounty, Roivant's long view on BD prospects for Immunovant's FcRn inhibitor, and more regulatory concerns around artificial intelligence. 

BIO Deals
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Services
  • Pharmaceuticals
    • OTC, Consumer
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Other Names / Subsidiaries
    • Accucaps Industries Limited
    • Catalent U.K. Swindon Zydis Limited
    • Cook Pharmica LLC
    • Juniper Pharmaceuticals
    • Molecular Profiles Ltd.
    • Columbia Laboratories, Inc.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By